Your browser doesn't support javascript.
loading
Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
Boursier, Jérôme; Guillaume, Maeva; Bouzbib, Charlotte; Lannes, Adrien; Pais, Raluca; Smatti, Sarra; Cariou, Bertrand; Bureau, Christophe; Ganne-Carrié, Nathalie; Bourlière, Marc; de Lédinghen, Victor.
Afiliação
  • Boursier J; Service d'hépato-gastroentérologie et oncologie digestive, CHU Angers, Angers, France. Electronic address: JeBoursier@chu-angers.fr.
  • Guillaume M; Cabinet de gastro-entérologie, endoscopie et maladies du foie, Clinique Pasteur, Toulouse, France.
  • Bouzbib C; Service d'Hépatologie, Hopital Pitié Salpêtrière, APHP, Paris, France.
  • Lannes A; Service d'hépato-gastroentérologie et oncologie digestive, CHU Angers, Angers, France.
  • Pais R; Service d'Hépatologie, Hopital Pitié Salpêtrière, APHP, Paris, France.
  • Smatti S; Service endocrinologie, diabète, nutrition, Hôpital Laennec, CHU Nantes, Saint-Erblain, France.
  • Cariou B; Service endocrinologie, diabète, nutrition, Hôpital Laennec, CHU Nantes, Saint-Erblain, France.
  • Bureau C; Service d'hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, France.
  • Ganne-Carrié N; Service d'hépatologie, Hôpital Avicenne, APHP, Université Sorbonne Paris Nord, Bobigny, France; INSERM UMR 1138, Centre de Recherche des Cordeliers, Université de Paris, France.
  • Bourlière M; Service d'hépato-gastroentérologie, Hôpital Saint Joseph, France; INSERM UMR 1252 IRD SESSTIM Aix Marseille Université, Marseille, France.
  • de Lédinghen V; Service d'hépato-gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France; INSERM U1053, Université de Bordeaux, Bordeaux, France.
Clin Res Hepatol Gastroenterol ; 46(1): 101769, 2022 01.
Article em En | MEDLINE | ID: mdl-34332133
ABSTRACT
NAFLD is a frequent disease that affects 25% of the worldwide population. There is no specific diagnostic test for NAFLD, and the diagnosis mainly relies on the elimination of the other causes of chronic liver diseases with liver biopsy kept for unsure diagnoses. Non-invasive tests are now available to assess NAFLD severity and therefore to help physicians decide on the patient management and follow-up. These non-invasive tests can also be used to define pathways that organize referrals from primary care and diabetology clinics to the liver specialist, with the ambition to improve the screening of asymptomatic patients with NAFLD and advanced liver disease. NAFLD being the liver expression of the metabolic syndrome, physicians need also take care to screen for diabetes and to evaluate the cardiovascular risk in those patients. These recommendations from the French Association for the Study of the Liver (AFEF) aim at providing guidance on the following questions how to diagnose NAFLD; how non-invasive tests should be used to assess NAFLD severity; how to follow patients with NAFLD; when to perform liver biopsy in NAFLD; and how to decide referral to the liver specialist for a patient with NAFLD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Imagem por Elasticidade / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article